ArticleInflammopharmacology2025
A novel in vivo adjuvant activity of hydrocarbon isolated from Hippophae rhamnoides.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new generation vaccines containing purified antigens are safer to use but generally induce weaker immune responses. Therefore, purified subunit vaccines require the addition of an exogenous adjuvant to enhance the immune response to the antigens following immunization. In the present study, a molecule has been isolated and characterized from 70% ethanolic extract of the medicinal plant Hippophaerhamnoides L. (Elaeagnaceae), commonly known as seabuckthorn (SBT). In this study, we have fractionated SBT leaf extract using solvents to identify the bioactive compound(s) and evaluated its adjuvant efficacy with weak antigen ovalbumin in balb/c mice. The identified bioactive compound was found to have a hydrocarbon moiety and was identified as alkane (named SSFa1), which in combination with ovalbumin boost humoral response in terms of high antibody titers, cell-mediated immune response such as T cell activation marker (CD27), and increased nitric oxide and proinflammatory cytokines (TNF-a and IL-6) production by peritoneal macrophages.
Indexed as
Identifiers
40650688What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.